BioXcel Therapeutics (BTAI)
(Real Time Quote from BATS)
$0.61 USD
-0.03 (-3.97%)
Updated Aug 30, 2024 01:38 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Income Statements
Fiscal Year end for BioXcel Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 0 | 0 | 0 |
Cost Of Goods | 1 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 172 | 160 | 107 | 82 | 34 |
Income After Depreciation & Amortization | -172 | -160 | -107 | -82 | -34 |
Non-Operating Income | 6 | 2 | 0 | 0 | 1 |
Interest Expense | 13 | 8 | 0 | 0 | 0 |
Pretax Income | -179 | -166 | -107 | -82 | -33 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -179 | -166 | -107 | -82 | -33 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -179 | -166 | -107 | -82 | -33 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -171 | -159 | -107 | -82 | -33 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -172 | -160 | -107 | -82 | -34 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 29.13 | 28.02 | 26.37 | 21.68 | 16.29 |
Diluted EPS Before Non-Recurring Items | -6.15 | -5.92 | -4.05 | -3.79 | -2.02 |
Diluted Net EPS (GAAP) | -6.15 | -5.92 | -4.05 | -3.79 | -2.02 |
Fiscal Year end for BioXcel Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.10 | 0.58 | 0.38 | 0.34 | 0.46 |
Cost Of Goods | 0.06 | 0.08 | 0.71 | 0.51 | 0.03 |
Gross Profit | 1.04 | 0.50 | -0.34 | -0.17 | 0.43 |
SG&A, R&D, and Dept/Amort Expenses | 18.34 | 24.66 | 19.53 | 48.13 | 52.84 |
Income After SG&A, R&D, and Dept/Amort Expenses | -17.30 | -24.16 | -19.87 | -48.30 | -52.41 |
Non-Operating Income | 12.70 | 0.98 | 1.05 | 1.06 | 2.16 |
Interest Expense | 3.70 | 3.61 | 3.44 | 3.25 | 3.26 |
Pretax Income | -8.30 | -26.79 | -22.26 | -50.49 | -53.52 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -8.30 | -26.79 | -22.26 | -50.49 | -53.52 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.30 | -26.79 | -22.26 | -50.49 | -53.52 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 40.25 | 30.87 | 29.45 | 29.27 | 29.19 |
Diluted EPS Before Non-Recurring Items | -0.21 | -0.87 | -0.76 | -1.72 | -1.83 |
Diluted Net EPS (GAAP) | -0.21 | -0.87 | -0.76 | -1.72 | -1.83 |